Summary.-The cytotoxicity of hexamethylmelamine (HMM) and its metabolites pentamethylmelamine (PMM), N,2,2,4,6-tetramethylmelamine (TMM) and hydroxymethylpentamethylmelamine (HMPMM) and of the alkylating agent triethylenemelamine (TEM) were studied on a cell line derived from a human ovarian cancer, by measuring [3H]TdR uptake.
HEXAMETHYLMELAMINE (HMM) is an
anticancer drug which in Phase II trials has shown consistent activity in several human malignancies (Blum et al., 1973; Legha et al., 1976) ; its effectiveness has been demonstrated in ovarian cancer (Wilson et al., 1969) and oat-cell carcinoma of the lung (Takita & Didolkar, 1974) .
The mechanism of action of HMM is unknown and, despite its structural similarity to triethylenemelamine (TEM) it does not appear to act as an alkylating agent (Worzalla et al., 1973) . For this reason it can be used in combination therapy or in patients who have become resistant to these drugs (Johnson et al., 1978; Bonomi et al., 1979; Bolis et al., 1979) . HMM is extensively metabolized in vivo through successive N-demethylation (Bryan et al., 1968; Worzalla et al., 1974) during which intermediate methylols are purportedly formed (De Milo & Borkovec, 1968 ). An early short communication by Heere & Donelly (1971) showed that HMM inhibited nucleic acid synthesis much more than protein synthesis in Ehrlich ascites cells. More recent in vitro studies by Rutty & Connors (1977) and Rutty & Harrap (1978) have established that neither HMM nor its metabolites pentamethylmelamine (PMM) and tetramethylmelamine (TMM) display any cytotoxic activity on TLX/5 cells exposed for 2 h to 1000 Htg/ml, whereas at the same concentrations and conditions the monomethylol of HMM(HMPMM) was very active. These findings are, however, open to some debate, since TLX/5 cells are not the most suitable model for studying the mechanism of action of HMM because of their lack of response to the drug in vivo. It should be added that the concentrations used were about 1000 times those attainable in animal or human plasma after drug administration D'Incalci et al., 1978 D'Incalci et al., , 1979a ) and the contact time of 2 h was too short, considering that in animal tumours or cancer patients only prolonged treatment has measurable anticancer activity (Legha et al., 1974) .
In the light of these considerations we decided to investigate the in vitro activity of HMM and its metabolites at different concentrations and times of exposure, HMM, PMM, TMM, and TEM were supplied by Dr H. Wood, NCI, Bethesda, U.S.A., HMPMM by Dr A. Gescher, Aston University, Birmingham, UK; formaldehyde was purchased from Carlo Erba, Milan, Italy. Compounds were suspended in growth medium. All these compounds were completely dissolved in growth medium except HMM, the solubility of which at 100 Hg/ml was not complete.
In these experiments the contact time varied from 1 to 120 h, and the medium containing the drugs was renewed every 24 h. At the end of treatment the wells were emptied, washed again with PBS and filled with fresh drug-free medium for up to 72h recovery. 0.5 ,uCi [3H]TdR, sp. act., 1-9 Ci/mM (Schwarz Mann, Orangeburg, N.Y.) was added to the medium for the last 6 h of treatment or recovery.
Cytotoxicity was measured as a percentage of the [3H]TdR uptake by controls.
HMM and PMM were determined in the medium by gas-liquid chromatography with nitrogen detection after n-hexane extraction. This method, which has been described in detail elsewhere (D'Incalci et al., 1979a ) has a maximum sensitivity of 10 ng/ml.
The results of the in vitro experiments were analysed statistically by Dunnett's test using a total of 10-20 samples for each time and concentration.
RESULTS
In a preliminary experiment, incubation of E cells with HMM, PMM and TMM for 48 h at concenltrations ranging from 0 1 to 10 tg/ml did not reduce [3H]TdR uptake (Table I) . In a subsequent experiment (Fig. 1) HMM The potential metabolism of HMM by target cells was explored by measuring PMM in the culture medium after incubation of HMM for 24 h at the concentration of 1 jtg/ml. No GLC peak for PMM and HMPMM was detectable when the sensitivity was 10 ng/ml (Fig. 2) and HMM did not disappear from the system. DISCUSSION HMM and its metabolites PMM, TMM and HMPMM all inhibit [3H]TdR uptake by E cells, a line derived from a human ovarian tumour. This effect is demonstrable at the very high concentrations of 100 tg/ml for 24 h, or for HMM and HMPMM at the lower concentration of 04I g/ml for 120 h. Concentrations of 10 jug/ml for 24-48 h did not produce any cytotoxicity in our experimental conditions, whereas the 100-fold lower concentration for 120 h did. It therefore appears that the potency of these compounds considerably increases with longer incubation time. This suggests that to improve the clinical efficacy of HMM treatment, it may be more important to keep constant, longlasting plasma concentrations than to raise the dose.
If we consider the available pharmacokinetic data in humans, we see that after a single oral dose of 120-300 mg/m 2 of HMM the plasma peak of HMM is reached in 0 5-4 h and ranges from 0-2 to 20 jg/ml. The plasma level then rapidly declines, followed by a slower phase of disappearance, so that after 12 h the concentration of H1MM ranges from 0.02 to 1P2 ,ug/ml and after 24 h from 0 01 to 0 3 jug/ml (D'Incalci et al., 1978, 1 979b) . On the basis of these pharmacokinetic data we would conclude that the concentrations of HMM we found cytotoxic in vitro are comparable with those present in the plasma of patients under treatment with the drug. Bryan et al. (1968) identified all the Ndemethylated metabolites in human plasma, and the activity of each was evaluated by Lake et al. (1975) who reported that HMM, PMM, TMM had similar potency, but the potency was progressively much lower for the other demethylated compounds. In patients treated with HMM, plasma levels of PMM and TMM reflect those of HMM but are always 2-10 times lower (D'Incalci et al., 1979b, and unpublished data) .
In our in vitro system PMM and TMM were as cytotoxic as HMM, so it is reasonable to assume that the N-demethylated metabolites, or at least PMM and TMM, play a minor role in HMM in vivo activity because they are present at lower concentrations. As expected from previous reports, HMPMM is very active on the E-cell line too, but we do not know the relevance of this finding; in fact even though HMPMM was recently found to be a major metabolite of HMM incubated with mice microsomes in vitro (Gescher et al., 1979) it has never been identified in vivo. Rutty and Connors (1977) reported an increase of formaldehyde concentrations in plasma of HMM-treated mice, which indirectly suggests that HMPMM and other methylols are formed in vivo. The study by Kaneko & Lepage (1978) in ll 633 which line KLN205 from mouse tumours was found sensitive to HMM in vivo but not in vitro, also suggests that some metabolites other than HMM could be responsible for the anticancer effect. The release of formaldehyde has been offered to explain the mode of action of HMM, but reportedly the formaldehyde inhibitor semicarbazide did not prevent HMPMM toxicity (Rutty & Connors, 1977 ) though a more recent report claims that it did reverse toxicity at a very low HMPMM concentration (Rutty & Harrap, 1978) . Our data also suggest that formaldehyde could be responsible for HMPMM activity; the ability of semicarbazide to reverse HMPMM cytotoxicity also in our system is currently being investigated.
We failed to find any metabolism of HMM by E cells, which might explain the cytotoxicity observed in terms of activation to HMPMM. In spite of our negative results, however, this hypothesis cannot be excluded, as the sensitivity of our method of detecting PMM or HMPMM (10 ng/ml) may not be sufficient considering the relatively small number of cells in our system.
Further study is warranted to confirm these data on primary cultures of ovarian cancer, where in some cases it is possible to predict the clinical efficacy (Salmon et al., 1978) and to establish whether HMM and its metabolites are cytotoxic at even lower concentrations if the contact time is fturther prolonged.
